Identifying ideal candidates for nanoliposomal topoisomerase inhibitors in metastatic pancreatic adenocarcinoma.

Identifying ideal candidates for nanoliposomal topoisomerase inhibitors in metastatic pancreatic adenocarcinoma. Clin Adv Hematol Oncol. 2018 Sep;16 Suppl 17(9):9-10 Authors: Yu K PMID: 30807562 [PubMed - in process]

https://www.ncbi.nlm.nih.gov/pubmed/30807562?dopt=Abstract

Source: Clinical Advances in Hematology and Oncology - February 27, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

More News: Adenocarcinoma | Cancer & Oncology | Hematology | Nanotechnology | Pancreas